LIVIVO - Search results -

Search results

Result 1 - 10 of total 17

Search options

Article ; Online: Repurposing old drugs as antiviral agents for coronaviruses.

Yang, Cheng-Wei / Peng, Tzu-Ting / Hsu, Hsing-Yu / Lee, Yue-Zhi / Wu, Szu-Huei / Lin, Wen-Hsing / Ke, Yi-Yu / Hsu, Tsu-An / Yeh, Teng-Kuang / Huang, Wen-Zheng / Lin, Jiunn-Horng / Sytwu, Huey-Kang / Chen, Chiung-Tong / Lee, Shiow-Ju

Biomedical journal

2020 Volume 43, Issue 4, Page(s) 368–374

Abstract: ... All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use ... approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due ... pandemic are urgently needed. One possible strategy is the repurposing of existing drugs ...

Abstract	Background: New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2. Methods: FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC Results: Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC Conclusion: All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients.
MeSH term(s)	Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Coronavirus OC43, Human/drug effects ; Drug Repositioning/methods ; Humans ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; SARS-CoV-2
Chemical Substances	Antiviral Agents
Keywords	covid19
Language	English
Publishing date	2020-05-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	2698541-X
ISSN	2320-2890 ; 2319-4170
ISSN (online)	2320-2890
ISSN	2319-4170
DOI	10.1016/j.bj.2020.05.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Repurposing old drugs as antiviral agents for coronaviruses

Cheng-Wei Yang / Tzu-Ting Peng / Hsing-Yu Hsu / Yue-Zhi Lee / Szu-Huei Wu / Wen-Hsing Lin / Yi-Yu Ke / Tsu-An Hsu / Teng-Kuang Yeh / Wen-Zheng Huang / Jiunn-Horng Lin / Huey-Kang Sytwu / Chiung-Tong Chen / Shiow-Ju Lee

Biomedical Journal, Vol 43, Iss 4, Pp 368-

2020 Volume 374

Abstract: ... values ranging from 11 nM to 75 μM. They are all old drugs as follows, anisomycin, antimycin ... oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. Conclusion: All of the old drugs identified ... approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due ...

Abstract	Background: New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2. Methods: FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC50) of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined. The viabilities of Fcwf-4 and HCT-8 cells were measured by crystal violet staining and MTS/PMS assay, respectively. Results: Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC50 values ranging from 11 nM to 75 μM. They are all old drugs as follows, anisomycin, antimycin A, atovaquone, chloroquine, conivaptan, emetine, gemcitabine, homoharringtonine, niclosamide, nitazoxanide, oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. Conclusion: All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients.
Keywords	Coronavirus ; COVID-19 ; Cytopathic effect ; HCoV-OC43 ; SARS-CoV-2 ; Drug repurpose ; Medicine (General) ; R5-920 ; Biology (General) ; QH301-705.5 ; covid19
Subject code	610
Language	English
Publishing date	2020-08-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Repurposing old drugs as antiviral agents for coronaviruses

Biomed J

Abstract: ... values ranging from 11 nM to 75 µM. They are all old drugs as follows, anisomycin, antimycin ... oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. CONCLUSION: All of the old drugs identified ... approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due ...

Abstract	BACKGROUND: New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2. METHODS: FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC50) of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined. The viabilities of Fcwf-4 and HCT-8 cells were measured by crystal violet staining and MTS/PMS assay, respectively. RESULTS: Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC50 values ranging from 11 nM to 75 µM. They are all old drugs as follows, anisomycin, antimycin A, atovaquone, chloroquine, conivaptan, emetine, gemcitabine, homoharringtonine, niclosamide, nitazoxanide, oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. CONCLUSION: All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #342672
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Repurposing old drugs as antiviral agents for coronaviruses

Yang, CW;Peng, TT;Hsu, HY;Lee, YZ;Wu, SH;Lin, WH;Ke, YY;Hsu, TA;Yeh, TK;Huang, WZ;Lin, JH;Sytwu, HK;Chen, CT;Lee, SJ

2020

Abstract: ... values ranging from 11 nM to 75 μM. They are all old drugs as follows, anisomycin, antimycin ... oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. CONCLUSION: All of the old drugs identified ... approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due ...

Abstract	BACKGROUND: New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to the commercial unavailability of SARS-CoV-2 drugs for treating COVID-19, we screened approximately 250 existing drugs or pharmacologically active compounds for their inhibitory activities against feline infectious peritonitis coronavirus (FIPV) and human coronavirus OC43 (HCoV-OC43), a human coronavirus in the same genus (Betacoronavirus) as SARS-CoV-2. METHODS: FIPV was proliferated in feline Fcwf-4 cells and HCoV-OC43 in human HCT-8 cells. Viral proliferation was assayed by visualization of cytopathic effects on the infected Fcwf-4 cells and immunofluorescent assay for detection of the nucleocapsid proteins of HCoV-OC43 in the HCT-8 cells. The concentrations (EC(50)) of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined. The viabilities of Fcwf-4 and HCT-8 cells were measured by crystal violet staining and MTS/PMS assay, respectively. RESULTS: Fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both FIPV and HCoV-OC43, with EC(50) values ranging from 11 nM to 75 μM. They are all old drugs as follows, anisomycin, antimycin A, atovaquone, chloroquine, conivaptan, emetine, gemcitabine, homoharringtonine, niclosamide, nitazoxanide, oligomycin, salinomycin, tilorone, valinomycin, and vismodegib. CONCLUSION: All of the old drugs identified as having activity against FIPV and HCoV-OC43 have seen clinical use in their respective indications and are associated with known dosing schedules and adverse effect or toxicity profiles in humans. Those, when later confirmed to have an anti-viral effect on SARS-CoV-2, should be considered for immediate uses in COVID-19 patients.
Keywords	covid19
Subject code	610
Language	en-US
Publishing date	2020-05-23
Publishing country	tw
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Challenges of rapamycin repurposing as a potential therapeutic candidate for COVID-19: implications for skeletal muscle metabolic health in older persons.

Lees, Matthew J / Hodson, Nathan / Tinline-Goodfellow, Cassidy T / Fung, Hugo J W / Elia, Antonis / Moore, Daniel R

American journal of physiology. Endocrinology and metabolism

2022 Volume 322, Issue 6, Page(s) E551–E555

Abstract: ... administered globally, several clinical trials are ongoing to repurpose existing drugs to combat severe ... the reduced relevance of drug repurposing for present or future pandemics. ... agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that has spread worldwide, resulting ...

Abstract	The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that has spread worldwide, resulting in over 6 million deaths as of March 2022. Older people have been disproportionately affected by the disease, as they have a greater risk of hospitalization, are more vulnerable to severe infection, and have higher mortality than younger patients. Although effective vaccines have been rapidly developed and administered globally, several clinical trials are ongoing to repurpose existing drugs to combat severe infection. One such drug, rapamycin, is currently under study for this purpose, given its immunosuppressant effects that are mediated by its inhibition of the mechanistic target of rapamycin (mTOR), a master regulator of cell growth. Consistent with this premise, acute rapamycin administration in young healthy humans blocks or attenuates mTOR and its downstream effectors, leading to the inhibition of muscle protein synthesis (MPS). Skeletal muscle mass declines when MPS is chronically lower than muscle protein breakdown. This is consequential for older people who are more susceptible to anabolic resistance (i.e., the blunting of MPS) due to reduced activity, sedentariness, or bed rest such as that associated with COVID-19 hospitalization, and who have also demonstrated a delayed or blunted ability to regain inactivity-induced muscle loss. The lack of studies investigating rapamycin administration on skeletal muscle in older people, and the emergence of effective antiviral medications against severe infection, may indicate the reduced relevance of drug repurposing for present or future pandemics.
MeSH term(s)	Aged ; Aged, 80 and over ; COVID-19/drug therapy ; Drug Repositioning ; Humans ; Muscle Proteins ; Muscle, Skeletal ; SARS-CoV-2 ; Sirolimus ; TOR Serine-Threonine Kinases
Chemical Substances	Muscle Proteins ; TOR Serine-Threonine Kinases (EC 2.7.11.1) ; Sirolimus (W36ZG6FT64)
Language	English
Publishing date	2022-05-06
Publishing country	United States
Document type	Editorial ; Research Support, Non-U.S. Gov't
ZDB-ID	603841-4
ISSN	1522-1555 ; 0193-1849
ISSN (online)	1522-1555
ISSN	0193-1849
DOI	10.1152/ajpendo.00064.2022
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.89: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.

Lentini, Giovanni / Cavalluzzi, Maria Maddalena / Habtemariam, Solomon

Molecules (Basel, Switzerland)

2020 Volume 25, Issue 8

Abstract: The desperate need to find drugs for COVID-19 has indicated repurposing strategies as our quickest ... way to obtain efficacious medicines. One of the options under investigation is the old ... related to accelerated large-scale clinical trials of drugs with unproven efficacy, the known potential ...

Abstract	The desperate need to find drugs for COVID-19 has indicated repurposing strategies as our quickest way to obtain efficacious medicines. One of the options under investigation is the old antimalarial drug, chloroquine, and its analog, hydroxychloroquine. Developed as synthetic succedanea of cinchona alkaloids, these chiral antimalarials are currently in use as the racemate. Besides the ethical concern related to accelerated large-scale clinical trials of drugs with unproven efficacy, the known potential detrimental cardiac effects of these drugs should also be considered. In principle, the safety profile might be ameliorated by using chloroquine/hydroxychloroquine single enantiomers in place of the racemate.
MeSH term(s)	Antimalarials ; Antiviral Agents/adverse effects ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Arrhythmias, Cardiac/chemically induced ; Betacoronavirus ; Cardiotoxicity ; Chloroquine/adverse effects ; Chloroquine/chemistry ; Chloroquine/pharmacology ; Chloroquine/therapeutic use ; Coronavirus Infections/drug therapy ; Drug Repositioning ; Humans ; Hydroxychloroquine/adverse effects ; Hydroxychloroquine/chemistry ; Hydroxychloroquine/therapeutic use ; Pandemics ; Pneumonia, Viral/drug therapy ; Stereoisomerism
Chemical Substances	Antimalarials ; Antiviral Agents ; Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF)
Keywords	covid19
Language	English
Publishing date	2020-04-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	1413402-0
ISSN	1420-3049 ; 1431-5165 ; 1420-3049
ISSN (online)	1420-3049
ISSN	1431-5165 ; 1420-3049
DOI	10.3390/molecules25081834
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.MO 81: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Covid-19, chloroquine repurposing, and cardiac safety concern

Lentini, G. / Cavalluzzi, M. M. / Habtemariam, S.

Chirality might help

2020

Abstract	The desperate need to find drugs for COVID-19 has indicated repurposing strategies as our quickest way to obtain efficacious medicines. One of the options under investigation is the old antimalarial drug, chloroquine, and its analog, hydroxychloroquine. Developed as synthetic succedanea of cinchona alkaloids, these chiral antimalarials are currently in use as the racemate. Besides the ethical concern related to accelerated large-scale clinical trials of drugs with unproven efficacy, the known potential detrimental cardiac effects of these drugs should also be considered. In principle, the safety profile might be ameliorated by using chloroquine/hydroxychloroquine single enantiomers in place of the racemate.
Keywords	2019-nCoV ; Chiral switch ; COVID-19 ; Ebola ; Hydroxychloroquine ; MERS ; Repositioning ; SARS ; SARS-cov-2 ; Antimalarials ; Antiviral Agents ; Arrhythmias ; Cardiac ; Cardiotoxicity ; Chloroquine ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia ; Viral ; Stereoisomerism ; Betacoronavirus ; Drug Repositioning ; covid19
Language	English
Publishing country	it
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.

Hage-Melim, Lorane Izabel da Silva / Federico, Leonardo Bruno / de Oliveira, Nayana Keyla Seabra / Francisco, Viviane Cristina Cardoso / Correia, Lenir Cabral / de Lima, Henrique Barros / Gomes, Suzane Quintana / Barcelos, Mariana Pegrucci / Francischini, Isaque Antônio Galindo / da Silva, Carlos Henrique Tomich de Paula

Life sciences

2020 Volume 256, Page(s) 117963

Abstract: The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract ...

Abstract	The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract called COVID-19. Structures of the main protease of SARS-CoV-2 (M
MeSH term(s)	Antiviral Agents/adverse effects ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; Betacoronavirus/isolation & purification ; COVID-19 ; Computer Simulation ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Drug Design ; Drug Development ; Drug Repositioning ; Humans ; Molecular Docking Simulation ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; Pyrazoles/pharmacology ; Pyridones/pharmacology ; SARS-CoV-2 ; COVID-19 Drug Treatment
Chemical Substances	Antiviral Agents ; Pyrazoles ; Pyridones ; apixaban (3Z9Y7UWC1J)
Keywords	covid19
Language	English
Publishing date	2020-06-11
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	3378-9
ISSN	1879-0631 ; 0024-3205
ISSN (online)	1879-0631
ISSN	0024-3205
DOI	10.1016/j.lfs.2020.117963
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uc I Zs.368: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.

Tripathy, Satyajit / Dassarma, Barsha / Roy, Somenath / Chabalala, Hlupheka / Matsabisa, Motlalepula Gilbert

International journal of antimicrobial agents

2020 Volume 56, Issue 2, Page(s) 106028

Abstract: ... the option of repurposing old drugs, e.g. CQ/HCQ, particularly HCQ, for the treatment of SARS-CoV-2 infection ... suggesting that the age-old antimalarial drugs CQ/HCQ could be a potent therapeutic against COVID-19. Based ... as frontline drugs for the treatment and prophylaxis of human malaria. Since the first reported cases in Wuhan ...

Abstract	Chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have long been used worldwide as frontline drugs for the treatment and prophylaxis of human malaria. Since the first reported cases in Wuhan, China, in late December 2019, humans have been under threat from coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 (previously known as 2019-nCoV), subsequently declared a pandemic. While the world is searching for expedited approval for a vaccine, which may be only preventative and not a cure, physicians and country leaders are considering several concerted clinical trials suggesting that the age-old antimalarial drugs CQ/HCQ could be a potent therapeutic against COVID-19. Based on accumulating scientific reports, here we highlight the possible modes of action of CQ/HCQ that could justify its use against viral infections. Considering the global health crisis of the COVID-19 pandemic, the option of repurposing old drugs, e.g. CQ/HCQ, particularly HCQ, for the treatment of SARS-CoV-2 infection could be a good choice. CQ/HCQ has diverse modes of action, including alteration of the acidic environment inside lysosomes and late endosomes, preventing endocytosis, exosome release and phagolysosomal fusion, and inhibition of the host cytokine storm. One or more diverse mechanisms might work against viral infections and reduce mortality. As there is no cure for COVID-19, clinical testing of HCQ is urgently required to determine its potency against SARS-CoV-2, as this is the currently available treatment option. There remains a need to find other innovative drug candidates as possible candidates to enter clinical evaluation and testing.
MeSH term(s)	Angiotensin-Converting Enzyme 2 ; Antiviral Agents/pharmacology ; Betacoronavirus/metabolism ; COVID-19 ; Chloroquine/pharmacology ; Coronavirus Infections/drug therapy ; Coronavirus Infections/metabolism ; Drug Repositioning ; Humans ; Hydroxychloroquine/pharmacology ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/metabolism ; SARS-CoV-2
Chemical Substances	Antiviral Agents ; Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF) ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
Keywords	covid19
Language	English
Publishing date	2020-05-22
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2020.106028
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾

Article ; Online: In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking.

Cavasotto, Claudio N / Di Filippo, Juan I

Molecular informatics

2020 Volume 40, Issue 1, Page(s) e2000115

Abstract: ... a year, and for a novel drug, even longer; finding a new use to an old drug (drug repurposing) could be ... no vaccine or antiviral drug is available. While the development of a vaccine might take at least ... of a library built from approved drugs and compounds undergoing clinical trials, against three SARS-CoV-2 ...

Abstract	In December 2019, an infectious disease caused by the coronavirus SARS-CoV-2 appeared in Wuhan, China. This disease (COVID-19) spread rapidly worldwide, and on March 2020 was declared a pandemic by the World Health Organization (WHO). Today, over 21 million people have been infected, with more than 750.000 casualties. Today, no vaccine or antiviral drug is available. While the development of a vaccine might take at least a year, and for a novel drug, even longer; finding a new use to an old drug (drug repurposing) could be the most effective strategy. We present a docking-based screening using a quantum mechanical scoring of a library built from approved drugs and compounds undergoing clinical trials, against three SARS-CoV-2 target proteins: the spike or S-protein, and two proteases, the main protease and the papain-like protease. The S-protein binds directly to the Angiotensin Converting Enzyme 2 receptor of the human host cell surface, while the two proteases process viral polyproteins. Following the analysis of our structure-based compound screening, we propose several structurally diverse compounds (either FDA-approved or in clinical trials) that could display antiviral activity against SARS-CoV-2. Clearly, these compounds should be further evaluated in experimental assays and clinical trials to confirm their actual activity against the disease. We hope that these findings may contribute to the rational drug design against COVID-19.
MeSH term(s)	Antiviral Agents/chemistry ; COVID-19/drug therapy ; China ; Drug Repositioning ; Humans ; Molecular Docking Simulation ; SARS-CoV-2/chemistry ; Viral Proteins/antagonists & inhibitors ; Viral Proteins/chemistry
Chemical Substances	Antiviral Agents ; Viral Proteins
Keywords	covid19
Language	English
Publishing date	2020-08-18
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2537668-8
ISSN	1868-1751 ; 1868-1743
ISSN (online)	1868-1751
ISSN	1868-1743
DOI	10.1002/minf.202000115
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito